ITRMF — Iterum Therapeutics Share News
0.000.00%
Last trade - 00:00Iterum Therapeutics PLC expected to post a loss of 45 cents a share - Earnings Preview
Brief: Iterum Therapeutics Commences Rights Offering
Brief: Iterum Therapeutics Announces FDA Advisory Committee Meeting To Discuss NDA For Oral Sulopenem For Treating Uncomplicated Urinary Tract Infections
Iterum Therapeutics PLC reports results for the quarter ended in January - Earnings Summary
Iterum Therapeutics PLC expected to post a loss of 72 cents a share - Earnings Preview
Iterum Therapeutics PLC expected to post a loss of 72 cents a share - Earnings Preview
Brief: Iterum Therapeutics Resubmits New Drug Application To U.S. FDA For Oral Sulopenem
Brief: Iterum Therapeutics On April 3, Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule
Iterum Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
Brief: Iterum Therapeutics Reports Q4 And Full Year 2023 Financial Results
Iterum Therapeutics PLC expected to post a loss of 93 cents a share - Earnings Preview
Iterum Therapeutics PLC expected to post a loss of 93 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Silver miners, Albemarle, Pfizer
U.S. STOCKS ON THE MOVE-Couchbase, Foot Locker, Nordstrom
Iterum rises on plans to submit marketing application for UTI drug earlier
Brief: Iterum Therapeutics Says Resubmission Of NDA For Oral Sulopenem To US FDA Is On Track For First Half Of Q2 2024
U.S. STOCKS ON THE MOVE-SLB, Corning, 2seventy Bio
Iterum Therapeutics rises on positive UTI drug trial result
Maxim initiates Iterum with 'buy'